scholarly journals Clinical utility of diagnostic biomarkers in malignant pleural mesothelioma: a systematic review and meta-analysis

2021 ◽  
Vol 30 (162) ◽  
pp. 210057
Author(s):  
Eline Schillebeeckx ◽  
Jan P. van Meerbeeck ◽  
Kevin Lamote

Malignant pleural mesothelioma (MPM) is characterised by late-stage diagnosis and poor prognosis. Currently, no screening tool is advocated and diagnosis is based on invasive techniques, which are not well tolerated. Non-invasive diagnostic biomarkers have shown potential and could have a huge clinical benefit. However, despite extensive research, there is no consensus yet on their clinical use, with many articles reporting contradicting results, limiting their clinical implementation. The aim of this systematic review is therefore to explore the different semi- and non-invasive diagnostic markers in several human matrices and identify those that might clinically be relevant. A total of 100 articles were selected through Web of Science and PubMed, with 56 articles included in the quantitative analysis. Although many studies have reported on the diagnostic accuracy of MPM biomarkers such as serum mesothelin and high-mobility group box protein 1 and plasma fibulin-3, none have resulted in a validated test for early detection. Future research should focus on external validation, combinations into biomarker panels, the inclusion of early stage MPM patients and a combination of different biomarker matrices, as well as new markers.

Oncotarget ◽  
2016 ◽  
Vol 7 (51) ◽  
pp. 84851-84859 ◽  
Author(s):  
Ran Ren ◽  
Pengpeng Yin ◽  
Yan Zhang ◽  
Jianyun Zhou ◽  
Yixing Zhou ◽  
...  

2014 ◽  
Vol 433 ◽  
pp. 44-48 ◽  
Author(s):  
Zhi-De Hu ◽  
Xiao-Fei Liu ◽  
Xiao-Cui Liu ◽  
Chun-Mei Ding ◽  
Cheng-Jin Hu

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3291
Author(s):  
Alex Dipper ◽  
Nick Maskell ◽  
Anna Bibby

For a number of patients presenting with an undiagnosed pleural effusion, frailty, medical co-morbidity or personal choice may preclude the use of pleural biopsy, the gold standard investigation for diagnosis of malignant pleural mesothelioma (MPM). In this review article, we outline the most recent evidence on ancillary diagnostic tests which may be used to support a diagnosis of MPM where histological samples cannot be obtained or where results are non-diagnostic. Immunocytochemical markers, molecular techniques, diagnostic biomarkers and imaging techniques are discussed. No adjunctive test has a sensitivity and specificity profile to support use in isolation; however, correlation of pleural fluid cytology with relevant radiology and supplementary biomarkers can enable an MDT-consensus clinico-radiological-cytological diagnosis to be made where further invasive tests are not possible or not appropriate. Diagnostic challenges surrounding non-epithelioid MPM are recognised, and there is a critical need for reliable and non-invasive investigative tools in this population.


2021 ◽  
Vol 10 (4) ◽  
pp. 1856-1862
Author(s):  
Lei Zhang ◽  
Qianghua Zhou ◽  
Yan-Qiu Han ◽  
Peng Li ◽  
Pei-Heng Ouyang ◽  
...  

Oncotarget ◽  
2017 ◽  
Vol 8 (59) ◽  
pp. 100640-100647 ◽  
Author(s):  
Zi-Yi Zhao ◽  
Sha-Sha Zhao ◽  
Meng Ren ◽  
Zi-Ling Liu ◽  
Zhi Li ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document